RadNet, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. RadNet operated 363 imaging centers across seven states and reported Imaging Centers and Artificial Intelligence (AI) segments. Amounts below are in U.S. dollars; financial statement amounts are generally shown in millions.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Service revenue | $403.7 | $354.4 | $794.3 | $696.1 |
| Operating income | $24.4 | $19.6 | $31.1 | $17.8 |
| Operating margin | 6.1% | 5.5% | 3.9% | 2.6% |
| Net income (loss) attributable to RadNet common stockholders | $8.4 | $7.9 | $(12.6) | $10.9 |
| Diluted EPS | $0.12 | $0.13 | $(0.21) | $0.18 |
| Adjusted EBITDA, including AI losses (non-GAAP) | $60.4 | $51.3 | $108.6 | $89.5 |
- Revenue and volumes: Q2 revenue grew 13.9% year over year. Same-center revenue rose 7.5% and same-center procedure volume 6.8%. For the first half, revenue increased 14%; same-center revenue and volume grew 7.4% and 7.6%, respectively.
- Profit drivers: First-half operating income improved, but RadNet common stockholders had a $12.6 million attributable loss despite $0.3 million consolidated net income. The difference reflects $12.9 million attributable to noncontrolling interests. First-half pretax income was only $0.8 million; interest expense rose to $31.8 million from $23.0 million.
- Cash flow: First-half operating cash flow was $100.7 million, versus $65.7 million. Investing cash outflow was $105.9 million, including $95.4 million of property and equipment purchases and $10.3 million for acquisitions. Financing cash inflow was $234.3 million, mainly reflecting the stock offering.
- Liquidity: Cash was $356.7 million at June 30, compared with $127.8 million at year-end. Working capital, excluding current operating lease liabilities, was $228.0 million, versus negative $41.9 million. Management said existing resources, operating cash flow and borrowing capacity should fund operations for at least the next 12 months.
- Debt: Total debt obligations were $864.3 million, including $856.8 million of term-loan face value and equipment notes; carrying value was lower after discounts. No amounts were drawn on either revolving facility. Available capacity was $187.4 million under the Barclays revolver and $50.0 million under the Truist revolver. RadNet reported compliance with all debt covenants.
Material changes and operating developments
- In June, RadNet sold 8,711,250 shares at $29.75 per share, generating $246.2 million net proceeds, intended for working capital and general corporate purposes. Shares outstanding increased from 57.7 million at December 31, 2022 to 67.7 million at June 30, 2023.
- Cost of operations rose 12.3% in the first half, below revenue growth; the cost ratio improved to 87.8% of revenue from 89.2%. Higher staffing, medical supplies and other operating costs reflected increased volumes, inflation and infrastructure needs. Medical supply expense rose 41.4% in the first half, including greater use and higher prices for contrast agents and PYLARIFY.
- First-half capital expenditures increased to $95.4 million from $72.7 million. The company acquired imaging assets for $10.2 million in the first half and added a net 10 centers. A further center acquisition for approximately $0.6 million closed August 1, after the reporting period.
- AI revenue more than doubled in the first half to $4.5 million, but the segment recorded a $14.9 million net loss, compared with $9.5 million. AI operating loss was $14.7 million. RadNet expects AI to continue generating losses in the near term while it commercializes products.
Outlook, risks and unusual items
- No specific numeric financial guidance is provided in the supplied filing text. Management expects higher effective rates and related interest expense to continue near term. At June 30, a hypothetical 1% rate increase was estimated to add approximately $2.1 million annual interest expense on First Lien Term Loans and $1.5 million on the Truist Term Loan.
- Interest-rate swaps have $500 million total notional value, with maturities in October 2023 and October 2025. RadNet received approximately $6.7 million in swap cash payments during Q2. A noncash fair-value gain on the swaps was $4.2 million in Q2 2023, compared with $6.3 million in Q2 2022; first-half gains were only $0.1 million, compared with $27.1 million in the prior-year period.
- Other risks noted include the capital-intensive business model, reliance on debt and covenant compliance, reimbursement and collection estimates, inflation and staffing costs, acquisition integration, AI commercialization, and foreign-currency exposure. The filing estimates a 1% decline in relevant foreign exchange rates would increase annual operating expenses by approximately $0.3 million.
- Acquisition-related contingent consideration included $7.2 million for Aidence milestones, $5.3 million for Quantib share holdback and $14.4 million for Heart and Lung Imaging milestones. A $1.2 million Montclair contingent-consideration liability was settled with a gain in Q2. The Quantib share holdback was settled July 7, 2023, after quarter-end.
- Management stated that pending legal matters were not expected to have a material adverse effect based on information available, while acknowledging outcomes are uncertain. The filing reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether same-center procedure and revenue growth can continue, and how much reported growth depends on acquisitions or added centers.
- How higher interest rates, swap maturities and debt amortization affect interest expense, cash generation and covenant headroom.
- Why first-half common-stockholder results were negative despite positive consolidated net income, including the impact of noncontrolling interests and noncash hedge valuation changes.
- Whether AI products can grow recurring commercial revenue and reduce segment losses; also track milestone-related contingent liabilities.
- How the public-offering proceeds are deployed and how the substantial increase in shares outstanding affects per-share results.